Lymphoma Immunotherapy: Current Status (original) (raw)

Targeted immunotherapy in Hodgkin lymphoma

Martin Hutchings

Blood, 2015

View PDFchevron_right

Novel Strategies to Improve Rituximab Efficacy in Non-Hodgkin's Lymphomas

Peertechz Journals

View PDFchevron_right

Non-Hodgkin's lymphomas, version 2.2014

Lubomir Sokol

Journal of the National Comprehensive Cancer Network : JNCCN, 2014

View PDFchevron_right

Current Concepts in Lymphoma Biology: Effect on Management and Outcome

Irfan Maghfoor

View PDFchevron_right

Non-Hodgkin's lymphomas, version 4.2014

Lubomir Sokol

Journal of the National Comprehensive Cancer Network : JNCCN, 2014

View PDFchevron_right

Current advances, problems and prospects for vaccine-based immunotherapy in follicular non-Hodgkin's lymphoma

Said Dermime

Leukemia & Lymphoma, 2005

View PDFchevron_right

Emergence of Novel Agents for Treatment of Hodgkin Lymphoma

Nahla Hamed

Cancer therapy & oncology international journal, 2017

View PDFchevron_right

Pubblicazione 11 Targeting B-cell non Hodgkin lymphoma New and old tricks

Antonio Giovanni Solimando

View PDFchevron_right

Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab

G. Dastoli

Critical Reviews in Oncology/Hematology, 2001

View PDFchevron_right

Monoclonal antibody therapy for classical Hodgkin lymphoma

Jan Walewski

Clinical Investigation, 2013

View PDFchevron_right

Antibody Therapy in Aggressive Lymphomas

Thomas Habermann

Hematology, 2007

View PDFchevron_right

Nivolumab-based immunotherapy in relapsed/refractory B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma

vadim baykov

2021

View PDFchevron_right

Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma

Maria Jesús Blanco

View PDFchevron_right

Update on epidemiology and therapeutics for non-Hodgkin's lymphoma

Janet Dancey

Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2002

View PDFchevron_right

Biological Pathways in B-cell Non-Hodgkin's Lymphoma

Mohit Aggarwal

2009

View PDFchevron_right

Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas

Stefania Crisci

Frontiers in Oncology

View PDFchevron_right

How I treat nodular lymphocyte predominant Hodgkin lymphoma

Richard Hoppe

Blood, 2013

View PDFchevron_right

4 Hodgkin ’ s Lymphoma

Luis De La Cruz-merino

2018

View PDFchevron_right

Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives

V. Augusti, Federico Carbone

Clinical and Developmental Immunology, 2010

View PDFchevron_right

Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas

Julia Rincon

Cancer Treatment Reviews, 2015

View PDFchevron_right

Nodular Lymphocyte Predominant Hodgkin Lymphoma: An Immunophenotypic Reappraisal Based on a Single-Institution Experience

Robert Pearcey

American Journal of Clinical Pathology, 2003

View PDFchevron_right

T cell mediated immunotherapy for B cell lymphoma

Joachim Schultze

Journal of Molecular Medicine, 1999

View PDFchevron_right

Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells

Alexandar Tzankov

Frontiers in Oncology

View PDFchevron_right

Non-Hodgkin's lymphomas, version 1.2013

nadeem zafar

Journal of the National Comprehensive Cancer Network : JNCCN, 2013

View PDFchevron_right

Radioimmunotherapy of B-cell non-Hodgkin's lymphoma

Jacques Barbet

European Journal of …, 2001

View PDFchevron_right

A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma

Robert Brown

Oncotarget

View PDFchevron_right

Aggressive non-Hodgkin’s lymphoma – long-term survival for all patients?

Jacques Tabacof

Hematology Meeting Reports, 2009

View PDFchevron_right

Novel therapeutics for Hodgkin\'s lymphoma

abhijit trailokya

Southeast Asian journal of health professionals, 2024

View PDFchevron_right

Novel agents for B-cell non-Hodgkin lymphoma: Science and the promise

Wyndham Wilson

Blood Reviews, 2010

View PDFchevron_right

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

Monic Stuart

…, 2004

View PDFchevron_right

Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results

Martin Dyer

Journal of Clinical Oncology, 2009

View PDFchevron_right